The Needle-Free Drug Delivery Market: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Release Date: May 2018
Number of Pages: 181
Number of Tables and Figures: 52

Needle-based Injections continue to be the primary option for the delivering large molecule drugs which would break down in the gastrointestinal tract if consumed orally. Despite their common use, needles have several drawbacks including but not limited to needle stick injuries, patient non-compliance and needle phobia. Furthermore, needles can be a source of disease transmission, particularly when they are re-used and used incorrectly.
To address these shortcomings, a number of needle-free drug delivery platforms have emerged. Among the potential alternatives are needle-free injections, transdermal patches, microneedles, nasal sprays and inhalers. Significant R&D investments are also being made in the oral delivery of large molecules.
Needle-free drug delivery platforms promise to make the administration of injectable drugs more efficient and less painful. Despite challenges relating to manufacturing, formulation complexities and regulation, SNS Pharma estimates that needle-free drug delivery will grow to a $6 Billion market by the end of 2021.
The “Needle-Free Drug Delivery Market: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the needle-free drug delivery ecosystem including delivery technologies, market drivers, challenges, investment potential, application areas, leading products, opportunities, key trends, regulatory landscape,  future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for needle-free drug delivery from 2018 through to 2030. The forecasts are segmented for 5 delivery platforms, 5 application areas, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a Sample and Table of Contents please contact [email protected]

Pricing: The report is available for the following price:

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings: 
  • Despite challenges relating to manufacturing, formulation complexities and regulation, SNS Pharma estimates that needle-free drug delivery will grow to a $6 Billion market by the end of 2021.
  • In terms of delivery platform categorization, we expect that needle-free injections will continue to dominate the market with an estimated market share of approximately 36% in 2021 – driven by adoption in multiple areas including pediatrics, vaccine delivery, pain relief, diabetes and growth hormone therapy.
  • Significant R&D investments are also being made in other areas such as smart pills studded with tiny needles that can deliver injectable drugs into the stomach lining – with a major focus on the delivery of biotherapeutics.
  • For example, Novartis, AstraZeneca and Shire are actively evaluating the oral delivery of selected biologics using a smart pill platform developed by Rani Therapeutics.
  • The needle-free drug delivery sector is continuing to consolidate with several prominent M&A deals such as Ferring Pharmaceuticals' acquisition of Antares Pharma's ZomaJet needle-free auto injector device, and Inovio Pharmaceuticals' takeover of Bioject Medical Technologies in a bid to combine the latter's jet injection technology with the former's needle-free, skin-surface electroporation technology.

Topics Covered:
The report covers the following topics: 
  •  Needle-free drug delivery ecosystem
  •  Market drivers and barriers
  •  Technology, economics and key trends
  •  Analysis of key application areas
  •  Needle-free injections, nasal, pulmonary, transdermal and oral drug delivery platforms 
  •  Advanced needle-based drug delivery platforms
  •  Active and passive drug delivery mechanisms
  •  Regulatory landscape of needle-free drug delivery throughout the globe
  •  Industry roadmap and value chain
  •  Profiles and strategies of over 80 leading ecosystem players, including drug delivery specialists and pharmaceutical giants
  •  Strategic recommendations for ecosystem players
  •  Market analysis and forecasts from 2018 till 2030

Forecast Segmentation
Market forecasts are provided for each of the following submarkets and their subcategories:

Delivery Platform
  • Needle-Free Injections
  • Nasal & Pulmonary Delivery
  • Transdermal Delivery
  • Advanced Needle-Based Platforms
  • Oral & Other Delivery Platforms

Application Area
  • Diabetes
  • Pediatrics
  • Pain Relief
  • Vaccination
  • Other Applications

Regional Markets
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • North America
  • Latin & Central America

Country Markets
  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey
  • UK
  • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the needle-free drug delivery opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2021 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • How big is the market for advanced needle-based drug delivery devices?
  • How does regulation impact the adoption of needle-free drug delivery platforms?
  • Who are the key market players and what are their strategies?
  • How will the growing adoption of generic drugs impact the market?
  • What are the future prospects of oral platforms for delivering biologics and other injectable drugs?
  • What strategies should needle-free platform providers and drug developers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

3M
Activa Brand Products
Adapt Pharma
AdminMed (nanoBioSciences)
Aequus Pharmaceuticals
Agile Therapeutics
AirXpanders
Akra Dermojet
Allergan
Altran Group
Amgen
Antares Pharma
ANVISA (Brazilian Health Surveillance Agency)
AstraZeneca
Battelle
Baxter
BD
Bespak
bioCSL
Bioject Medical Technologies
Cambridge Consultants
Catalent
CDSCO (Central Drugs Standard Control Organization, India)
CFDA (China Food and Drug Administration)
COFEPRIS (Federal Commission for the Protection against Sanitary Risks, Mexico)
Consort Medical
Corium International
Crossject
CSL Group
DCI (D’Antonio Consultants International)
Debiotech
EDA (Egyptian Drug Authority)
EMA (European Medicines Agency)
Endo International
Enesi Pharma
EPG (European Pharma Group)
Ferring Pharmaceuticals
Genexine
GSK (GlaxoSmithKline)
Haselmeier
Health Canada
Hospira
Ichor Medical Systems
ICURE Pharmaceutical
Immune Design
Impel NeuroPharma
InCube Labs
INJEX Pharma/Abel Health Technologies
Inovio Pharmaceuticals
Invectys
Israeli MoH (Ministry of Health)
ITI (Immunomic Therapeutics, Inc.)
Janssen Pharmaceutical Companies
Johnson & Johnson
Keystone Industries
Lenis Medical
MannKind Corporation
MCC (Medicines Control Council, South Africa)
MedImmune
Merck and Co.
Merck KGaA
MFDS (Ministry of Food and Drug Safety, South Korea)
MHLW (Ministry for Health Labor and Welfare, Japan)
Ministry of Health and Family Welfare, India
MIT (Massachusetts Institute of Technology)
MIT Canada (Medical International Technologies)
MK Global/Mika Medical
Mundipharma International
Mylan
NanoPass Technologies
National Medical Products
Nemaura Pharma
Nemera
Novartis
P&G (Procter & Gamble)
Penjet Corporation
Pfizer
PharmaJet
PharmBioTec
PKA SoftTouch Corporation
PMDA (Pharmaceuticals and Medical Devices Agency, Japan)
Portal Instruments
Prometheon Pharma
Rani Therapeutics
Russian MoH (Ministry of Healthcare)
Saarland University
Sanofi
Seagull Technologies
Seqirus
SFDA (Saudi Food and Drug Authority)
Shire
Smiths Medical
Takeda Pharmaceutical Company
Terumo Corporation
Teva Pharmaceutical Industries
The Medicines Company
TheraJect
TSI (Transdermal Specialties, Inc.)
TSK Laboratory
Tyndall National Institute
U.S. FDA (Food and Drug Administration)
University of Queensland
Vaccibody
Valeritas
Vaxxas
WHO (World Health Organization)
Ypsomed
Zogenix
Zosano Pharma Corporation
Zynerba Pharmaceuticals